H.C. Wainwright analyst Ed Arce raised the firm’s price target on Pliant Therapeutics to $54 from $53 and keeps a Buy rating on the shares. The firm says Pliant continues to make progress on its lead program while advancing the rest of its pipeline.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PLRX:
- Pliant Therapeutics price target lowered to $50 from $55 at Citi
- Pliant: Enrollment for Phase 2a bexotegrast trial has commenced following review
- 3 Stocks to Buy Today, 3/13/2023, According to Top Analysts
- Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
- Pliant Therapeutics price target lowered to $58 from $60 at RBC Capital
